The CEO of Danish pharmaceutical giant Novo Nordisk, known for its blockbuster weight-loss drug Ozempic, will step down, the ...

Novo Nordisk CEO Lars Fruergaard Jorgensen will step down as the company faces challenges in the obesity drug market, which ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Novo Nordisk announced the resignation of CEO Lars Fruergaard Jorgensen amidst recent market challenges and fluctuating share prices. The company will conduct a search for a successor as Jorgensen ...

It’s the end of an era at Novo Nordisk as longtime CEO Lars Fruergaard Jørgensen—who recently shepherded the company through its GLP-1 growth boom—heads for the exit. | Under a mutual agreement with ...

Open crisis at the top of the Danish company famous for its anti-obesity and anti-diabetes drugs that in September 2023 had ...

“Serving as Novo Nordisk’s CEO for the past eight years has been ... to defeat serious chronic diseases.” Jørgensen’s resignation is one of multiple high-profile departures at Novo ...

Discover the latest executive changes across major companies like UnitedHealth, Intuitive, Novo Nordisk, and more.

What happened to 23andMe? Here's a look at its history from launch to bankruptcy and acquisition by Regeneron.